1. Brown G, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl JMed 323:1289, 1990.

2. Ginsberg HN. Lipoprotein physiology in non-diabetic and diabetic states: Relationship to atherogenesis. Diabetes Care 14:839,1991.

3. Grundy SM HMG-Co-A Reductase inhibitors for treatment of hyperc-holesterolemia. N Engi J Med 319:24, 1988.

4. Grundy SM, Vega GL. Two different views of the relationship of hyper-triglyceridemia to coronary heart disease: Implications of treatment. Arch Intern Med 152:28, 1992.

5. Havel RJ. Lowering cholesterol 1988: Rationale mechanisms and means. JClin Invest 81:1653, 1988.

6. Henkin Y et al Secondary hyperlipidemia: Inadvertent effects of drugs in clinical practice. JAMA 267:961, 1992.

7. Joven JJ, et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engi J Med 323:579,1990.

8. LaRosa JC. Therapy of the hyperlipoproteinemias. In KL Becker, et al (eds), Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott, 1990. Pp. 1241.

9. Mahley RW, et al. Genetic defects in lipoprotein metabolism: Elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA 265:78,1991.

10. NIH Consensus Conference. Triglycerides, high-density lipoproteins and coronary heart disease. JAMA 269:505, 1993.

11. Report of the National Cholesterol Education Program expert panel on detection evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 148:36,1988.

12. Scanu AM Lipoprotein (a). A genetic risk factor for premature coronary heart disease. JAMA 267:3326, 1992.

13. Schaefer EJ. Hyperlipoproteinemias and other lipoprotein disorders. In KL Becker et al, (eds), Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott, 1990. Pp. 1229.

14. Steinberg I, et al. Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N Engi J Med 320:915,1989.

15. Suh IL et al. Alcohol use and mortality from coronary heart disease: The role of high-density lipoprotein cholesterol. Ann Intern Med 881, 1992.

16. Watts GF, et al. Effects on coronary artery disease of lipid- lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regressions Study (STARS). Lancet 339:563, 1992.